Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID 19 all comers meta-analysis

sarilumab phase 2 high dose unpublished
 
NCT04315298
RCTsarilumab high dose (400mg)placeboCOVID 19 all comershigh
145/77 suggested
    no demonstrated benefit a
  • suggested 61 % decrease in death or ventilation but with a low degree of certainty due to high risk of bias
  • suggested 73 % decrease in ventilation but with a low degree of certainty due to high risk of bias
there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group
sarimulab phase 2 low dose unpublished
 
NCT04315298
RCTsarilumab low dose (200mg)placeboCOVID 19 all comershigh
136/77 suggested
    no demonstrated benefit a
  • suggested 72 % decrease in ventilation but with a low degree of certainty due to high risk of bias
there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group

COVID 19 hospitalized meta-analysis

Colaneri, 2020OBStocilizumab controlCOVID 19 hospitalizedcritical
21/21 inconclusive
    no demonstrated benefit a
HNF Hospital Tocilizumab multidisciplinary team, 2020OBStocilizumab controlCOVID 19 hospitalizedcritical
20/25 suggested
  • suggested 87 % decrease in death or transfer to ICU but with a very low degree of certainty due to critical risk of bias
Martinez-Sanz, 2020OBStocilizumab controlCOVID 19 hospitalizedcritical
260/969 suggested
  • suggested 66 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
Tsai, 2020OBStocilizumab controlCOVID 19 hospitalizedserious
66/66 inconclusive
    no demonstrated benefit a

COVID-19 mild to moderate meta-analysis

CORIMUNO-19, 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
64/67 inconclusive
    no demonstrated benefit a
EMPACTA, 2020
 
NCT04372186
RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
259/129 conclusif
  • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 45 % decrease in clinical worsening with a moderate degree of certainty due to some concern in risk of bias
RCT-TCZ-COVID-19, 2020
 
NCT04346355
RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
60/66 inconclusive
    no demonstrated benefit a
  • inconclusive 5 % increase in clinical worsening (PE) with a moderate degree of certainty due to some concern in risk of bias
Capra, 2020OBStocilizumab controlCOVID-19 mild to moderatecritical
62/23 suggested
  • suggested 96 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

COVID-19 severe or critically meta-analysis

BACC Bay Tocilizumab Trial, 2020
 
NCT04356937
RCTtocilizumab placeboCOVID-19 severe or criticallylow
161/81 inconclusive
    no demonstrated benefit a
  • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
294/144 inconclusive
    no demonstrated benefit a
Andrew, 2020OBStocilizumab controlCOVID-19 severe or criticallyNA
198/413 inconclusive
    no demonstrated benefit a
ARI-RAF (Della-Torre), 2020OBSsarilumabcontrolCOVID-19 severe or criticallyNA
28/28 inconclusive
    no demonstrated benefit a
Biran, 2020OBStocilizumab controlCOVID-19 severe or criticallyserious
210/420 suggested
  • suggested 36 % decrease in deaths but with a low degree of certainty due to high risk of bias
Mathilde, 2020OBStocilizumab controlCOVID-19 severe or criticallycritical
30/29 suggested
  • suggested 75 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
Rojas-Marte, 2020OBStocilizumab controlCOVID-19 severe or criticallycritical
96/97 inconclusive
    no demonstrated benefit a
Somers, 2020OBStocilizumab controlCOVID-19 severe or criticallycritical
78/76 safety concern
  • suggested 45 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
  • statistically significant 2.3-fold increase in superinfection but with a very low degree of certainty due to critical risk of bias
TOCI-RAF Study Group (Campochiaro), 2020OBStocilizumab controlCOVID-19 severe or criticallyNA
32/33 inconclusive
    no demonstrated benefit a

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);